Sign In
Last checked at 
2 Aug 2022 07:00
Syncona Limited
Total Voting Rights
2 August 2022
Pursuant to DTR 5.6.1 Syncona Limited (the "Company") announces that as at 29 July 2022 the total number of ordinary shares in issue now stands at 669,329,324 and the total number of voting rights in the Company is 669,329,324.
The Company does not hold any ordinary shares in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
[ENDS]
Enquiries
Syncona LtdNatalie Garland-Collins / Fergus WittTel: +44 (0) 7714 916615
About Syncona
Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses, across development stage and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com.
Follow the stocks
